Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2016
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 14 Jun 2016 Status changed from recruiting to completed.
- 10 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 10 Feb 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.